Teva Realigns, may Slash 25% of Workforce
Kåre Schultz, new chief executive officer of debt-plagued Israeli drugmaker Teva, is moving rapidly to make good on his pledge to improve the company’s financial performance and reposition it...
View ArticleFDA Approves Mylan’s Herceptin Biosimilar
The US Food and Drug Administration (FDA) has given the green light to Netherlands-domiciled, US-managed generic drugmaker Mylan’s Ogivri (trastuzumab-dkst) breast cancer drug, a biosimilar to the...
View ArticleMylan and Fujifilm arm Join up on Biosimilar
Mylan has joined forces with Japan’s Fujifilm Kyowa Kirin Biologics to commercialize a biosimilar to Abbvie’s Humira (adalimumab) that has been developed by the Japanese company. read more
View ArticlePfizer Under Pressure in EpiPen Shortage
Mylan is leaning on Pfizer to do more to relieve shortages of the EpiPen Auto-Injector. Although the drugmaker based in the US and the UK owns the rights to the EpiPen, which is recommended to prevent...
View ArticleFDA Approves Teva’s Generic EpiPen
After two years of trying, Israeli generics producer Teva Pharmaceutical Industries has finally gained approval by the US Food and Drug Administration (FDA) for its copy of Mylan’s EpiPen. The FDA has...
View ArticleDCAT Announces New Board of Directors
Paolo Magri, senior vice president, business development at Advitech, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT). Also elected to serve as...
View ArticleUS States Sue Drugmakers Over Price-fixing
A coalition of 44 US states has filed a 500-page lawsuit against 20 leading generic drugmakers supplying the domestic market. The companies are accused of operating a sweeping scheme to raise prices by...
View ArticlePfizer Merges Upjohn With Mylan
New York-based US drugs giant Pfizer is merging its off-patent franchise, Upjohn, with generics specialist Mylan. The deal announced on Jul. 29 and expected to close in mid-2020 foresees a combined...
View ArticleContinuous Processing
Is it possible to learn from other industries or are we doomed to repeat the same mistakes in the pharma sector? Not long ago, I came across a Forbes article which described how streaming service...
View ArticleInjecting Growth and Innovation
Abbvie takes over Allergan, Pfizer merges its generics business with Mylan, Takeda integrates Shire — the pharmaceutical industry is making a name for itself in 2019 with several billion-dollar...
View Article
